Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Gritstone bio (Nasdaq: GRTS) is hosting a virtual key opinion leader (KOL) event on August 2, 2024, at 9:00 AM ET. The event will feature Dr. J. Randolph Hecht from UCLA and Howard Brown, a colorectal cancer survivor and advocate. They will discuss the unmet needs and current treatment landscape for metastatic microsatellite stable colorectal cancer (MSS-CRC).
Gritstone management will highlight their personalized neoantigen vaccine program, GRANITE, as a potential treatment for immunologically "cold" tumors, including MSS-CRC. The company expects to release mature progression-free survival data from a randomized Phase 2 study of GRANITE in frontline MSS-CRC in Q3 2024. The event will conclude with a live Q&A session.
Gritstone bio (Nasdaq: GRTS) ospiterà un evento virtuale con esperti di opinione chiave (KOL) il 2 agosto 2024, alle 9:00 AM ET. L'evento vedrà la partecipazione del Dr. J. Randolph Hecht dell'UCLA e di Howard Brown, un sopravvissuto al cancro colorettale e sostenitore. Discuteranno i bisogni insoddisfatti e il panorama attuale dei trattamenti per il cancro colorettale metastatico stabile microsatellitare (MSS-CRC).
La direzione di Gritstone metterà in luce il proprio programma di vaccini personalizzati a neoantigeni, GRANITE, come potenziale trattamento per tumori immunologicamente
Gritstone bio (Nasdaq: GRTS) llevará a cabo un evento virtual con líderes de opinión clave (KOL) el 2 de agosto de 2024, a las 9:00 AM ET. El evento contará con la participación del Dr. J. Randolph Hecht de UCLA y Howard Brown, un sobreviviente de cáncer colorrectal y defensor. Discutirán las necesidades no satisfechas y el panorama actual de tratamiento para el cáncer colorrectal metastásico estable en microsatélites (MSS-CRC).
La dirección de Gritstone destacará su programa de vacunas personalizadas con neoantígenos, GRANITE, como un tratamiento potencial para tumores inmunológicamente
Gritstone bio (Nasdaq: GRTS)는 2024년 8월 2일 오전 9시(ET)에 가상 주요 의견 리더(KOL) 행사를 개최합니다. 이 행사에는 UCLA의 J. Randolph Hecht 박사와 대장암 생존자이자 옹호자인 Howard Brown가 참석할 예정입니다. 그들은 전이성 마이크로새틀라이트 안정 대장암(MSS-CRC)의 충족되지 않은 요구와 현재 치료 현황에 대해 논의할 것입니다.
Gritstone 경영진은 MSS-CRC를 포함한 면역학적으로
Gritstone bio (Nasdaq: GRTS) organise un événement virtuel avec des leaders d'opinion (KOL) le 2 août 2024 à 9h00 ET. L'événement mettra en vedette le Dr J. Randolph Hecht de UCLA et Howard Brown, survivant du cancer colorectal et avocat. Ils discuteront des besoins non satisfaits et du paysage actuel des traitements pour le cancer colorectal métastatique stable aux microsatellites (MSS-CRC).
La direction de Gritstone mettra en avant son programme de vaccins personnalisés à néoantigènes, GRANITE, comme un traitement potentiel pour les tumeurs immunologiquement
Gritstone bio (Nasdaq: GRTS) veranstaltet am 2. August 2024, um 9:00 Uhr ET eine virtuelle Veranstaltung mit führenden Meinungsbildnern (KOL). Bei der Veranstaltung wird Dr. J. Randolph Hecht von der UCLA und Howard Brown, ein Überlebender von Darmkrebs und Fürsprecher, teilnehmen. Sie werden über die ungedeckten Bedürfnisse und die aktuelle Behandlungssituation für metastasierenden Mikrosatelliten-stabilen Dickdarmkrebs (MSS-CRC) sprechen.
Das Management von Gritstone wird sein personalisiertes Neoantigen-Impfprogramm, GRANITE, als potenzielle Behandlung für immunologisch
- None.
- None.
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) --
EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced it will host a virtual key opinion leader (KOL) event on Friday, August 2 at 9:00 AM ET featuring J. Randolph Hecht, MD, (Professor, UCLA Gastrointestinal Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) who will discuss the unmet need and current treatment landscape for patients with metastatic microsatellite stable colorectal cancer (MSS-CRC). To register, click here.
Gritstone management will also highlight the development of Gritstone’s personalized neoantigen vaccine program, GRANITE, as a potential treatment for immunologically “cold” tumors including MSS-CRC. Mature progression-free survival data from a randomized Phase 2 study of GRANITE in frontline MSS-CRC are expected in the third quarter of 2024.
A live Q&A session will follow the formal presentations.
About J. Randolph Hecht, MD
J. Randolph Hecht, MD is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has led and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents.
About Howard Brown
Howard Brown is a two-time Stage IV cancer patient, survivor, advocate, technology entrepreneur, husband, dad and avid basketball player. In 1989 at the age of 23, Howard was diagnosed with Stage IVe Non-Hodgkin’s Lymphoma. After failing three chemotherapy regimens, he had an allogeneic (from a donor) bone marrow transplant from his twin sister who was an exact HLA match. That, along with massive chemotherapy and full body radiation saved his life. Twenty-six years after achieving remission, Howard was diagnosed with Stage III Colon Cancer at age fifty via a standard colonoscopy. After two colon resection surgeries, intense chemotherapy and a failed clinical trial he turned metastatic Stage IV and discovered the cancer had spread to his liver, peritoneum, omentum and small bowel. After salvage second line chemotherapy showed some regression (shrinkage), Howard underwent Cytoreduction Surgery (debulking / removal of live and dead cancer cells) with Heated intra-peritoneal chemotherapy (hot chemo wash to kill micro cancer cells– (CRS HIPEC). Howard is currently considered No Evidence of Disease (NED) at this time after 9 consecutive CT scans. He serves as the Board Chair and President of Colontown, an organization that serves over 11,000 patients and caregivers with colorectal cancer. Howard is a proud graduate and past trustee of Babson College, #1 for entrepreneurship, and lives with his family in Birmingham, Michigan.
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone bio Contacts
Investors:
George E. MacDougall
Gritstone bio, Inc.
ir@gritstone.com
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
FAQ
When is Gritstone bio (GRTS) hosting its virtual KOL event on GRANITE?
Who are the featured speakers at Gritstone bio's (GRTS) KOL event?
What is the focus of Gritstone bio's (GRTS) GRANITE program?
When does Gritstone bio (GRTS) expect to release Phase 2 data for GRANITE in MSS-CRC?
